SCHEMBL4254460

SCHEMBL4254460

C=CCc1ccc(O)c(OC(C)=O)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 2/20 0.71
ALOX5 P09917 4/20 0.67
ALDH1A1 P00352 4/20 0.67
CYP3A4 P08684 2/20 0.67
AR P10275 1/20 0.67
TRPM8 Q7Z2W7 1/20 0.67
XDH P47989 1/20 0.54
GABRA1 P14867 5/20 0.53
GABRB2 P47870 5/20 0.53
MEN1 O00255 4/20 0.53
KMT2A Q03164 4/20 0.53
PPARG P37231 2/20 0.53
PPARD Q03181 2/20 0.53
CNR2 P34972 2/20 0.53
KDM4E B2RXH2 2/20 0.53
GAA P10253 2/20 0.53
MAPT P10636 2/20 0.53
ALDH2 P05091 1/20 0.53
AKR1B1 P15121 1/20 0.53
HPGD P15428 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL2450520 0.97 PTGS1 (0.68) PTGS1ALOX5ALDH1A1CYP3A4AR
Eugenyl Acetate SCHEMBL26667569 0.89 PTGS1 (0.87) PTGS1ALOX5ALDH1A1CYP3A4AR
SCHEMBL11891610 0.87 PTGS1 (0.85) PTGS1ALOX5ALDH1A1CYP3A4AR
Eugenyl Acetate SCHEMBL5138181 0.87 PTGS1 (0.82) PTGS1ALOX5ALDH1A1CYP3A4AR
Eugenyl Acetate SCHEMBL29802968 0.83 PTGS1 (1.00) PTGS1ALOX5ALDH1A1CYP3A4AR
Eugenyl Acetate SCHEMBL14764089 0.83 PTGS1 (1.00) PTGS1ALOX5ALDH1A1CYP3A4AR
Eugenol SCHEMBL29943804 0.83 ALDH1A1 (0.85) PTGS1ALOX5ALDH1A1CYP3A4AR
Eugenyl Acetate SCHEMBL112232 0.83 PTGS1 (1.00) PTGS1ALOX5ALDH1A1CYP3A4AR
Eugenol SCHEMBL114133 0.83 ALDH1A1 (0.85) PTGS1ALOX5ALDH1A1CYP3A4AR
SCHEMBL16679994 0.83 PTGS1 (0.89) PTGS1ALOX5ALDH1A1CYP3A4AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118948982-A Compositions comprising alpinia and other plant extracts for improving joint health and treating arthritis 尤尼根公司 2024-11-15 CN disclosed
CN-115515614-B Compositions comprising alpinia and other plant extracts for improving joint health and treating arthritis 尤尼根公司 2024-07-23 CN disclosed
CN-115515614-A Compositions comprising extracts of alpinia and other plants for improving joint health and treating arthritis 尤尼根公司 2022-12-23 CN disclosed
EP-2790536-A1 DEVICE AND METHOD FOR SIMULATING CHEMOSENSATION OF SMOKING Sentiens, LLC (US) 2014-10-22 EP disclosed
WO-2013090410-A1 DEVICE AND METHOD FOR SIMULATING CHEMOSENSATION OF SMOKING SENTIENS, LLC (US) 2013-06-20 WO disclosed
US-7629375-B2 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 2009-12-08 US disclosed
EP-1694335-A4 OSTEOCLASTOGENESIS INHIBITORS AND USES THEREOF RES DEV FOUNDATION (US) 2008-12-31 EP disclosed
CN-1309382-C 1'-acetoxyl chavicol acetate with anti-HIV activity and its derivatives HONGYI SCIENCE AND TECHNOLOGY (CN) 2007-04-11 CN disclosed
EP-1694335-A2 OSTEOCLASTOGENESIS INHIBITORS AND USES THEREOF RESEARCH DEVELOPMENT FOUNDATION (US) 2006-08-30 EP disclosed
US-20060178356-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods GALILEO PHARMACEUTICALS, INC. 2006-08-10 US disclosed
WO-2006046934-A2 OSTEOCLASTOGENESIS INHIBITORS AND USES THEREOF RESEARCH DEVELOPMENT FOUNDATION (US) 2006-05-04 WO disclosed
US-6939563-B2 Non-fermented osmotic laxative and method for treating and preventing colorectal cancers Inra-Institut National de la Recherche Agronomique (FR) 2005-09-06 US disclosed
EP-1435894-A4 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS GALILEO PHARMACEUTICALS INC (US) 2005-07-06 EP disclosed
US-20050142155-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods JOHNSON & JOHNSON CONSUMER INC. 2005-06-30 US disclosed
US-20050113416-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods GALILEO PHARMACEUTICALS, INC. 2005-05-26 US disclosed
EP-1435894-A2 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS Galileo Pharmaceuticals, Inc. (US) 2004-07-14 EP disclosed
CN-1457771-A 1'-acetoxyl chavicol acetate with anti-HIV activity and its derivatives HONGYI SCIENCE AND TECHNOLOGY (CN) 2003-11-26 CN disclosed
US-20030073712-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods JOHNSON & JOHNSON CONSUMER COMPANIES, INC. 2003-04-17 US disclosed
EP-1124566-B1 NON-FERMENTED OSMOTIC LAXATIVE FOR TREATING AND PREVENTING COLORECTAL CANCERS AGRONOMIQUE INST NAT RECH (FR) 2003-02-12 EP disclosed
WO-2003009807-A2 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS GALILEO LABORATORIES, INC. (US) 2003-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050142155-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods HSF1, HMOX1, NQO1 PTGS1 183/4885ALOX5 131/4885ALDH1A1 488/4885
US-20030073712-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods HSF1, HMOX1, NQO1 PTGS1 183/4885ALOX5 131/4885ALDH1A1 488/4885
US-20050113416-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods HSF1, HMOX1, NQO1 PTGS1 183/4885ALOX5 131/4885ALDH1A1 488/4885
US-20060178356-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods HSF1, HMOX1, NQO1 PTGS1 183/4885ALOX5 131/4885ALDH1A1 488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.